Skip to main content
OpenTrials
Completed

NCT Number: NCT00178425

PK of MMF in Cadaveric vs Living Donor Liver Transplant Recipients

The purpose of this study is to measure the amount of MMF and tacrolimus concentration in the blood at a given time. Currently MMF is ordered as a set dose and tacrolimus is given based on body weight. While the deceased donor transplant receives the complete liver, in the live donor just over half of the liver is given (about 60%). The way these different types of transplants break down drugs could be different. Measuring the drug levels allows us to know what happens to the medication in between the morning and the evening dose.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

University of Rochester

Rochester, New York, 14642, United States

About this study

The purpose of this study is to measure the amount of MMF and tacrolimus concentration in the blood at a given time. Currently MMF is ordered as a set dose and tacrolimus is given based on body weight. While the deceased donor transplant receives the complete liver, in the live donor just over half of the liver is given (about 60%). The way these different types of transplants break down drugs could be different. Measuring the drug levels allows us to know what happens to the medication in between the morning and the evening dose.

12 subjects with live liver donors and 12 subjects with deceased donors will be included in the study.

Each patient will have 12 (twelve) blood samples (half a teaspoon) drawn at 0,1, 2, 3, 4, 4½; 5, 6, 7, 8, 10 and 12 hours from an intravenous line placed during the operation. At the same time, 24-hour urine will be collected to measure your kidney function. After 4 to 6 days post transplant when the will be switched to oral MMF, again 10 (ten) blood samples a half teaspoon each will be drawn at 0, 1, 2, 3, 4, 5, 6, 8, 10, 12 hours. Blood will be drawn with the routine daily blood work for the first 14 days and then at 1 and 3 months after transplant. Total blood drawn over 3 months will be about 7 tablespoons. A 24-hour urine will be collected in a container given to you starting one day before the routine clinic visit (as a standard of care). The 24-hour urine will be collected at 1 and 3 months after transplant as well.

If a woman, who could become pregnant, a pregnancy test will be done before your transplant. They would also have to use birth control during the study period and 6 months after the completion of study.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Adult
  • Female patients
  • Negative pregnancy test
  • Willing for contraception during the study period and 6 weeks after study

Exclusion criteria

  • Serum Creatinine > 2.5 mg/dl
  • On Dialysis
  • HIV +ve
  • Re-transplantation
  • On Ventilator
  • Multi-organ Transplant
  • Platelets < 50,000
  • WBC < 2,500

Treatment and study plan

Serial blood sampling as described in protocol

Procedure

Estimation of Creatinine Clearance at regular intervals

Procedure

Primary outcomes

  1. Comparison of Pharmacokinetics of MMF in living donor liver transplant and deceased donor liver transplant

Secondary outcomes

  1. Comparison of Pharmacokinetics of IV MMF vs PO MMF

  2. Pharmacokinetics of tacrolimus after liver transplant

Sponsors and collaborators

Lead sponsor

University of Rochester

Other

Collaborators

  • Hoffmann-La Roche

Registry information

Official study title

Pharmacokinetics of Intravenous / Oral MMF and Oral Tacrolimus in Live Donor and Deceased Donor Liver Transplant Patients

Important dates

Study start
2005
Study completion
2006
First posted
Sep 15, 2005
Registry last updated
Apr 19, 2007

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.